Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on oncology therapeutics, announced that its annual meeting of shareholders will be held virtually at 9 a.m. PDT on June 29, 2026. Meeting materials will be mailed following finalization and filing with the Securities and Exchange Commission (SEC). The company also disclosed that its 2025 annual report included an audit report containing a going concern explanatory paragraph from its independent registered public accounting firm, as required under Section 610(b) of the NYSE American Company Guide. The disclosure does not reflect any change or amendment to previously filed financial statements.
A going concern qualification indicates that there is substantial doubt about the company's ability to continue operating for the foreseeable future. For investors, this raises questions about Kairos Pharma's financial stability and its capacity to fund ongoing clinical trials. The company is currently conducting a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer for its lead candidate, ENV-105, an antibody targeting CD105—a protein identified as a key driver of drug resistance and disease relapse. ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator. The company's focus on addressing significant unmet medical needs in oncology underscores the potential impact of its research, but the going concern notice highlights the financial challenges that biotech firms often face during the lengthy and costly drug development process.
The announcement is significant for shareholders and the broader biotech industry, as it signals potential risks associated with the company's financial health. Investors should monitor the company's ability to secure additional funding or partnerships to advance its clinical programs. The full press release is available at https://ibn.fm/sQ0pm. For the latest news and updates relating to KAPA, the company's newsroom can be accessed at https://ibn.fm/KAPA.
Kairos Pharma, based in Los Angeles, California, utilizes structural biology to overcome drug resistance and immune suppression in cancer. The going concern disclosure does not change previously filed financial statements but serves as a critical indicator for stakeholders evaluating the company's prospects. The virtual annual meeting will provide a platform for shareholders to engage with management on these issues and the company's strategic direction.
